Device Trial Radar · NCT04915924
Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
358
Actual
Start
Oct 30, 2020
Primary completion
Jun 2, 2024
Study completion Jun 2, 2024
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jun 7, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Korea HM3 PMS is a prospective, single arm, open-label, multi-center, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure. The PMS will enroll up to 300 patients, that meet the Health Insurance Review and Assessment (HIRA) guidelines for LVAD implantation, from up to 25 sites in South Korea. Subjects who will be implanted but not included in the PMS can be enrolled retrospectively after obtaining their informed consent. The surveillance period for this PMS is expected to be 4 years from the time of HM3 approval in Korea, concluding on June 2, 2024.
Conditions
- Advanced Heart Failure
Interventions
HeartMate 3™ left ventricular assist system (HM3 LVAS)Device
Advanced heart failure patients will be implanted with the HM3 LVAS
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Endpoint: Kaplan-Meier Success Rate of Overall Survival to Transplant, Myocardial Recovery or on Device Support Free of Debilitating Stroke (60 Days Post-stroke Modified Rankin Score >3) or Reoperation for Pump ReplacementTime frame: From enrollment to 36 months
- Primary Safety Endpoint: Number of Cumulative Occurrences of Adverse EventsTime frame: From enrollment until the study conclusion date (up to 43 months, 3 days)
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Korea University Ansan Hospital
Ansan, South Korea
Sejong Hospital
Bucheon-si, South Korea
Pusan National University Hospital
Busan, South Korea
19 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.